Published Paper Details:

The montelukast is a leukotrine receptor antagonist (LTRA) used for the maintenance treatment of asthma, chronic asthma attacks and to relieve symptoms of seasonal allergies. Because of poor bioavailability of montelukast sodium by oral route, there is a need to increase its bioavailability by formulating it into buccal dosage forms.The results of swelling index between the range of 30.03 - 44.27 %, and the surface pH was in the range pH of buccal region. The results of drug content were in the prescribed range. The in vitro residence time for all the patches is in between 3.20 - 5.59 hrs. The Bursting strength of patches is in the range of 4.166 to 5.733 Kg/cm 2. In vitro release studies were conducted for montelukast loaded patches exhibited drug release in the range of 68.83 - 92.22 % in 8 hrs. FT-IR studies revealed that, there was no interaction between drug and excipients used. Release of montelukast from all patches followed zero order and mechanism was diffusion rate limited. Finally it can be concluded that F3 and F6 are the best formulation.